SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for a U.S. Army program to develop 10 kV silicon-carbide power semiconductors is driving attention, with traders viewing the award as defense and technology validation. The reaction is tempered by concerns that it is a development-stage project with undisclosed financial terms and no clear near-term revenue impact.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing shares are under pressure after the FAA delayed 737 MAX 10 certification while reviewing a flight-management software glitch that can disrupt automated navigation in a specific landing scenario. Traders debate whether the setback signals deeper quality and leadership problems or is an overreaction to a manageable issue, with some buying the dip and others fearing further delays.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Positive Phase 3 DAYBREAK results in wet AMD drove a sharp rally: both Kodiak candidates met their primary goals, and Zenkuda showed potential for longer intervals between injections; the company plans an FDA filing. Traders celebrated the data and a possible short squeeze, while others questioned the stocks valuation and warned of profit-taking, financing needs, and remaining FDA risk.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is under pressure amid trader concerns that Googles publisher-payment pilot could weaken Reddits bargaining position or reduce the likelihood of a favorable AI data-licensing renewal; uncertainty around the separate Anthropic case also features in the discussion. Bears focus on deal risk and insider selling, while bulls argue Reddits user growth and data value still support the business.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

A sharp, sustained selloff ahead of Applied Digitals upcoming fiscal first-quarter report is driving attention. Traders disagree over whether the weakness reflects broader pressure on AI data-center stocks or company-specific concerns about execution, dilution and limited updates; some are buying the dip while others are wary of the report and guidance.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

A Defense Department grant to help convert a U.S. battery line for high-energy-density drone cells is the main catalyst drawing attention to Amprius. Many traders view the award as strategic validation and long-term growth support, while others caution it is not a purchase order or near-term revenue and note the initial rally quickly faded.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Kodiaks positive late-stage wet AMD results have pressured OCUL as traders reassess competition for AXPAXLI. The community is split: some see Kodiaks durability data as a threat, while others argue AXPAXLIs trial results and FDA path remain stronger and view the selloff as an overreaction.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

ACHR is drawing attention amid debate over Midnights development and execution: skeptics focus on the lack of a piloted transition and missed manufacturing goals, while bulls point to ongoing testing, flight tours, and the planned Boeing acquisitions as signs of progress. Some traders also attribute the stocks weakness to broader market and rate pressures.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBARs sharp, high-volume rally is being linked by traders to enterprise-AI developments, including an IBM Cloud identity integration and Hedera council members joining NVIDIAs Open Agent Safety Platform. Some traders instead attribute the move to momentum, a short squeeze, or crypto rotation, while others warn of profit-taking.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Attention centers on Summits pending FDA decision for ivonescimab, with traders weighing its positive clinical data against uncertainty over the survival evidence regulators require. Recent concerns about cash runway and potential financing have added pressure, while some investors point to insider buying and upcoming trial catalysts as reasons for optimism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Here's Why Alnylam Pharmaceuticals (ALNY) Declined

Here's Why Alnylam Pharmaceuticals (ALNY) Declined...

TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 8:45 AM ET in Everett...

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical...

If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.86% on an annualized basis producing an average annual return of 15.09%. Currently, Alnylam Pharmaceuticals has a marketread more...

IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY

Equity

Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.


BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum

BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Neutral Sentiment

Track ALNY stock price, charts, news and real-time market activity on Stocktwits. Join the ALNY message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Alnylam Pharmaceuticals Inc stock.

ALNY Stock Price Today - Alnylam Pharmaceuticals Inc News, Charts, Retail Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

ALNY Alnylam Pharmaceuticals Inc